tiprankstipranks
Trending News
More News >
Benitec Biopharma Ltd (BNTC)
NASDAQ:BNTC

Benitec Biopharma (BNTC) AI Stock Analysis

Compare
266 Followers

Top Page

BN

Benitec Biopharma

(NASDAQ:BNTC)

Rating:54Neutral
Price Target:
Benitec Biopharma's stock score reflects the company's financial instability and challenges in revenue generation, balanced by positive technical indicators and significant potential in its BB-301 study results. While the stock shows strong market momentum, the overbought conditions and negative valuation metrics suggest caution. The positive corporate event has bolstered the company's prospects, but sustained improvement in financial performance is needed to enhance long-term attractiveness.
Positive Factors
Clinical Trial Progress
Benitec Biopharma has made steady advances with the Phase 1b/2a trial of its lead clinical candidate, BB-301, with the sixth subject being safely treated with the low dose.
Efficacy and Safety
There have been no severe adverse events (SAEs) in any study subjects to date.
Financial Performance
Benitec Biopharma recorded a F3Q25 net loss of only $0.24 per share vs. the forecast of a net loss of $0.36 per share.
Negative Factors
Clinical Trial Risks
Risks include slower-than-expected progress in the ongoing clinical trial of BB-301 and the potential for emergence of unexpected side effects.
Data Robustness
The small number of patients in the trial limits the robustness of the data, and further evidence is needed to confirm a dose-response relationship.
Market Offering
The secondary offering includes pre-funded warrants to purchase an additional 300,000 shares.

Benitec Biopharma (BNTC) vs. SPDR S&P 500 ETF (SPY)

Benitec Biopharma Business Overview & Revenue Model

Company DescriptionBenitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
How the Company Makes MoneyBenitec Biopharma generates revenue primarily through partnerships, collaborations, and licensing agreements with other pharmaceutical and biotechnology companies. These agreements often involve upfront payments, milestone payments, and royalties based on the successful development and commercialization of therapies utilizing their ddRNAi technology. Additionally, Benitec may receive funding from grants and research institutions to support their research and development efforts.

Benitec Biopharma Financial Statement Overview

Summary
Benitec Biopharma shows financial instability with significant losses and negative cash flow. The income statement reveals declining revenue, significant net losses, and negative margins. The balance sheet is strong with a high equity ratio and low leverage, but ongoing net losses reflected in the negative return on equity are concerning. Despite a robust cash position, the cash flow statement highlights negative operating and free cash flow, indicating high cash burn without substantial revenue improvement.
Income Statement
20
Very Negative
The income statement shows a declining revenue trend with a significant net loss and negative margins. The TTM (Trailing-Twelve-Months) data indicates a gross profit margin of -2916.67%, a net profit margin of -356916.67%, and an EBIT margin of -401550%. Revenue growth is inconsistent, showing a decline compared to previous periods, reflecting challenges in generating sales.
Balance Sheet
50
Neutral
Benitec Biopharma's balance sheet shows a strong equity position with an equity ratio of 96.11% in TTM. However, the debt-to-equity ratio is low at 0.002, indicating minimal leverage. The return on equity is negative, reflecting ongoing net losses. The company maintains a robust cash position, providing some stability.
Cash Flow
30
Negative
The cash flow statement highlights negative operating cash flow and free cash flow in TTM. The free cash flow growth rate is negative, indicating cash burn. However, the company raised substantial financing, improving liquidity. The operating cash flow to net income ratio is close to 1, suggesting cash flow issues align with net losses.
Breakdown
TTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income StatementTotal Revenue
0.00216.00K75.00K73.00K59.00K97.00K
Gross Profit
-91.00K108.00K-306.00K64.00K-64.00K-171.06K
EBIT
-30.14M-22.49M-19.08M-17.85M-13.60M-8.28M
EBITDA
-29.94M-22.49M-18.70M-17.85M-13.60M-7.91M
Net Income Common Stockholders
-26.49M-21.75M-19.56M-18.56M-13.78M-8.30M
Balance SheetCash, Cash Equivalents and Short-Term Investments
103.58M50.87M2.48M4.06M19.77M9.80M
Total Assets
105.21M52.21M4.46M5.97M21.38M11.59M
Total Debt
959.00K284.00K559.00K811.00K213.00K405.00K
Net Debt
-102.62M-50.58M-1.92M-3.25M-19.56M-9.40M
Total Liabilities
7.64M4.96M4.26M3.09M1.37M1.35M
Stockholders Equity
97.57M47.25M202.00K2.88M20.01M10.24M
Cash FlowFree Cash Flow
-18.69M-19.58M-18.01M-15.91M-13.05M-7.63M
Operating Cash Flow
-18.67M-19.40M-18.01M-15.90M-12.83M-7.54M
Investing Cash Flow
-18.00K-179.00K-1.00K-13.00K-221.00K-94.00K
Financing Cash Flow
108.01M68.03M16.02M0.0022.52M1.77M

Benitec Biopharma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price16.00
Price Trends
50DMA
13.75
Positive
100DMA
12.94
Positive
200DMA
11.60
Positive
Market Momentum
MACD
0.56
Negative
RSI
63.84
Neutral
STOCH
68.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTC, the sentiment is Positive. The current price of 16 is above the 20-day moving average (MA) of 14.41, above the 50-day MA of 13.75, and above the 200-day MA of 11.60, indicating a bullish trend. The MACD of 0.56 indicates Negative momentum. The RSI at 63.84 is Neutral, neither overbought nor oversold. The STOCH value of 68.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BNTC.

Benitec Biopharma Risk Analysis

Benitec Biopharma disclosed 68 risk factors in its most recent earnings report. Benitec Biopharma reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
A number of our stockholders hold significant amounts of our common stock and unexercised warrants to acquire common stock, and therefore could exert significant influence over us. Q2, 2024

Benitec Biopharma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
64
Neutral
$451.61M-22.95%40.88%-579.73%
59
Neutral
$475.12M-83.24%-100.32%-197.69%
55
Neutral
$465.20M-115.47%
54
Neutral
$420.01M-48.57%-100.00%83.98%
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
53
Neutral
$622.74M181.41%3055.71%-18.80%
45
Neutral
$370.71M-1869.55%-60.19%56.60%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
BNTC
Benitec Biopharma
16.00
8.59
115.92%
CKPT
Checkpoint Therapeutics
4.26
2.32
119.59%
ETON
Eton Pharmaceuticals
16.84
13.24
367.78%
PHAT
Phathom Pharmaceuticals
8.92
-1.82
-16.95%
AMLX
Amylyx Pharmaceuticals Inc
5.33
3.57
202.84%
ZBIO
Zenas BioPharma, Inc.
11.12
-6.85
-38.12%

Benitec Biopharma Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Benitec Biopharma Announces Positive Interim Results for BB-301
Positive
Mar 19, 2025

On March 19, 2025, Benitec Biopharma announced positive interim results from its BB-301 Phase 1b/2a study, presented at the 2025 Muscular Dystrophy Association Conference. The study showed significant improvements in swallowing function for three subjects with Oculopharyngeal Muscular Dystrophy (OPMD), achieving clinically normal swallowing profiles and reducing dysphagic symptom burdens. These results highlight the potential of BB-301 as a promising treatment for OPMD, a condition with limited therapeutic options, and may enhance Benitec’s position in the gene therapy market.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.